Lung Cancer Clinical Trials
Stacey Bledsoe, RN, director of diversity in clinical trials at Eli Lilly and Company, talks about the importance of diversity in clinical trials
Doctors all over the world conduct research studies known as clinical trials. More than 100 scientists and physicians, nurses, social workers and technologists at the IU Simon Comprehensive Cancer Center dedicate their professional lives to advancing cancer care through clinical trials. Learn more about clinical trials.
Below are lung cancer clinical trials. For questions, email either Maggie Uhrich, muhrich@iu.edu, or Lori Tyson, lotyson@iu.edu.
14 protocol(s) meet the specified criteria
CTO-DSP107-001OPEN TO ACCRUAL
A FIRST-IN-HUMAN, TWO-PART, OPEN-LABEL, PHASE I/II STUDY OF DSP107 IN SUBJECTS WITH ADVANCED SOLID TUMORS INCLUDING A DOSE-ESCALATION SAFETY STUDY (PART 1) AND PRELIMINARY EFFICACY ASSESSMENT OF DSP107 AS MONOTHERAPY AND IN COMBINATION WITH ATEZOLIZUMAB (PART 2)
CTO-IUSCCC-0770TERMINATED
Serial Testing To Assess Cognitive Function In Patients With Cancer Being Treated With Immunotherapy
CTO-IUSCCC-0783OPEN TO ACCRUAL
Rapid ( Warm ) Autopsy Protocol for Patients with Small Cell Lung Cancer
CTO-IUSCCC-0865OPEN TO ACCRUAL
Exercise as Maintenance Therapy in Advanced Lung Cancer
CTO-IUSCCC-0868OPEN TO ACCRUAL
Comparing Stigma in Lung Cancer to Other Tobacco-Related Cancers: A Study from End Lung Cancer Now
CTO-IUSCCC-0876OPEN TO ACCRUAL
Expanding Lung Cancer Screening to Persons who do not Meet the 2021 USPSTF Guidelines Criteria: A Study from End Lung Cancer Now
CTO-KB707-02OPEN TO ACCRUAL
A Phase I Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs
CTO-LUN21-530OPEN TO ACCRUAL
A phase II trial of MOnaliZumab in combination with
durvAlumab (MEDI4736) plus platinum-based chemotheRapy
for first-line Treatment of extensive stage small cell lung cancer
(MOZART)
CTO-S1827OPEN TO ACCRUAL
MRI BRAIN SURVEILLANCE ALONE VERSUS MRI SURVEILLANCE AND PROPHYLACTIC CRANIAL IRRADIATION (PCI): A RANDOMIZED PHASE III TRIAL IN SMALL-CELL LUNG CANCER (MAVERICK)
CTO-S1900KOPEN TO ACCRUAL
A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study S1900k)
CTO-S2302CLOSED TO ACCRUAL
S2302, PRAGMATICA - LUNG: A PROSPECTIVE RANDOMIZED STUDY OF RAMUCIRUMAB
(LY3009806; NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD
OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV
OR RECURRENT NON-SMALL CELL LUNG CANCER
PHO-COG-AOST2031OPEN TO ACCRUAL
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma.
PULM-IIR-DRCOPEN TO ACCRUAL
Analysis of DRC in lung disease
S1900GOPEN TO ACCRUAL
A Randomized Phase II Study of INC280 (capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
